Cargando…

Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy

Introduction: Current gene therapy involves replacement of defective gene by delivery of healthy genetic material to precede normal function. Virus-mediated gene delivery is the most successful and efficient method for gene therapy, but it has been challenged due to serious safety concerns. Converse...

Descripción completa

Detalles Bibliográficos
Autores principales: Youn, Hyewon, Chung, June-Key
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696419/
https://www.ncbi.nlm.nih.gov/pubmed/26125492
http://dx.doi.org/10.1517/14712598.2015.1057563
_version_ 1782407792992190464
author Youn, Hyewon
Chung, June-Key
author_facet Youn, Hyewon
Chung, June-Key
author_sort Youn, Hyewon
collection PubMed
description Introduction: Current gene therapy involves replacement of defective gene by delivery of healthy genetic material to precede normal function. Virus-mediated gene delivery is the most successful and efficient method for gene therapy, but it has been challenged due to serious safety concerns. Conversely, gene delivery using plasmid DNA (pDNA) is considered safer, but its transfection efficiency is much lower than virus-mediated gene transfer. Recently, mRNA has been suggested as an alternative option to avoid undesired insertion of delivered DNA sequences with higher transfection efficiency and stability. Area covered: In this review, we summarize the currently available strategies of mRNA modification to increase the therapeutic efficacy; we also highlight the recent improvements of mRNA delivery for in vivo applications of gene therapy. Expert opinion: The use of mRNA-based gene transfer could indeed be a promising new strategy for gene therapy. Notable advantages include no risk of integration into the genomic DNA, adjustable gene expression and easier modulation of the immune system. By reducing or utilizing the immunogenic properties, mRNA offers a promising tool for gene/or transcript replacement.
format Online
Article
Text
id pubmed-4696419
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Informa Healthcare
record_format MEDLINE/PubMed
spelling pubmed-46964192016-01-12 Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy Youn, Hyewon Chung, June-Key Expert Opin Biol Ther Review Introduction: Current gene therapy involves replacement of defective gene by delivery of healthy genetic material to precede normal function. Virus-mediated gene delivery is the most successful and efficient method for gene therapy, but it has been challenged due to serious safety concerns. Conversely, gene delivery using plasmid DNA (pDNA) is considered safer, but its transfection efficiency is much lower than virus-mediated gene transfer. Recently, mRNA has been suggested as an alternative option to avoid undesired insertion of delivered DNA sequences with higher transfection efficiency and stability. Area covered: In this review, we summarize the currently available strategies of mRNA modification to increase the therapeutic efficacy; we also highlight the recent improvements of mRNA delivery for in vivo applications of gene therapy. Expert opinion: The use of mRNA-based gene transfer could indeed be a promising new strategy for gene therapy. Notable advantages include no risk of integration into the genomic DNA, adjustable gene expression and easier modulation of the immune system. By reducing or utilizing the immunogenic properties, mRNA offers a promising tool for gene/or transcript replacement. Informa Healthcare 2015-09-02 2015-06-30 /pmc/articles/PMC4696419/ /pubmed/26125492 http://dx.doi.org/10.1517/14712598.2015.1057563 Text en © The Author(s). Published by Informa UK, Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Review
Youn, Hyewon
Chung, June-Key
Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy
title Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy
title_full Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy
title_fullStr Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy
title_full_unstemmed Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy
title_short Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy
title_sort modified mrna as an alternative to plasmid dna (pdna) for transcript replacement and vaccination therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696419/
https://www.ncbi.nlm.nih.gov/pubmed/26125492
http://dx.doi.org/10.1517/14712598.2015.1057563
work_keys_str_mv AT younhyewon modifiedmrnaasanalternativetoplasmiddnapdnafortranscriptreplacementandvaccinationtherapy
AT chungjunekey modifiedmrnaasanalternativetoplasmiddnapdnafortranscriptreplacementandvaccinationtherapy